5723 results about "Intestino-intestinal" patented technology

The invention belongs to the technical field of biology, and discloses a reagent combination or kit for constructing intestinal organs and application of the reagent combination or kit. According to the reagent combination or the kit, intestinal organs can be obtained from cell-derived epithelial cells obtained from a donor in a non-invasive manner, and the obtained intestinal organs can be cryopreserved and recovered and can be amplified in vitro for a long time; transcriptome characteristics are similar to those of real human small intestine tissues, and typical marker genes of various small intestine pedigree cell types are highly expressed; compared with intestinal organs obtained through induction of pluripotent stem cells, the intestinal organs have more intestinal pedigree characteristics, and the intestinal function development is more mature; after being promoted to be mature, the intestinal organ also highly expresses genes related to drug absorption and metabolism, has drug absorption capability similar to that of an immortalized intestinal cell line, but more prominently shows intestinal cell lineage characteristics, is closer to an intestinal environment in a real human body, and can be used for screening intestinal disease drugs; the intestinal barrier function is realized.

The invention relates to the technical field of medical informatics, and discloses an intestinal flora associated disease risk prediction system based on multi-data set difference mutual identification, and the system comprises the steps: capturing the dynamic evolution characteristics of a network through constructing a species-genus-phylum three-level microbial interaction network, and employing a time sequence diagram convolution network; and designing a network disturbance experiment, introducing a network recovery force index to quantify the network recovery capability, constructing a network vulnerability map to identify key nodes and analyze a disturbance propagation path, and integrating stable and consistent network toughness characteristics in multiple data sets to establish an early warning mechanism. By means of the method, early and accurate early warning of disease risks is achieved, and a key time window is provided for clinical intervention.

The invention relates to lactobacillus rhamnosus CBBM005 and application thereof in products for balancing intestinal flora, improving immunity and improving oral cavity, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CBBM005 is separated from human intestinal secretion, the lactobacillus rhamnosus CBBM005 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation time is March 20, 2025, and the preservation number is CGMCC NO.33904. The lactobacillus rhamnosus CBBM005 has the characteristics of balancing intestinal flora, improving immunity and improving oral cavity.

The invention relates to the technical field of microorganisms, and discloses a multifunctional compound probiotic composition which comprises the following raw materials in percentage by mass: 40-50% of probiotics; 30%-40% of a microcapsule embedding material; prebiotics: 10%-25%; 1%-5% of auxiliary materials; the invention also provides a preparation process of the multifunctional compound probiotic composition. The preparation process comprises the following steps: S1, culturing the probiotics and detecting the activity; s2, a microencapsulation process: preparing a multi-layer microcapsule through a spray drying method and an emulsion crosslinking method, and embedding the probiotics; and S3, mixing the microcapsules with prebiotics and auxiliary materials to obtain the multifunctional compound probiotic composition. By adopting a composite probiotic compatibility technology and through the synergistic effect of different strains, the stability and functionality of intestinal microecology are enhanced, and the effects of improving the survival rate of probiotics in gastrointestinal tracts, promoting planting of beneficial bacteria and enhancing the immunoregulation ability are achieved.

The invention discloses an enteritis patient condition severity risk early warning method, a medium and equipment. The method comprises the following steps: acquiring a borborygmus original signal and a clinical multi-dimensional physiological parameter sequence through a sensing device; constructing a borborygmus dynamic characteristic spectrum based on the borborygmus original signal to generate an acoustic biomarker time sequence; inputting the acoustic biomarker time sequence and the clinical multi-dimensional physiological parameter sequence into a multi-modal fusion early warning model to obtain an intestinal inflammation risk index; executing a signal quality self-evaluation process and generating a data quality warning code when the signal quality is abnormal; triggering a multi-node collaborative monitoring mechanism based on the risk index to generate an intestinal state multi-dimensional situation map; establishing an individualized risk baseline and generating a graded early warning instruction; and finally outputting a comprehensive early warning report. According to the method, multi-modal fusion analysis of the borborygmus signal and the clinical parameters is realized, the accuracy and timeliness of illness state early warning are remarkably improved through dynamic risk assessment and signal quality monitoring, and a reliable basis is provided for clinical decision making.

The invention provides infant formula milk powder for improving intestinal inflammation and / or microbial disorder as well as a preparation method and application of the infant formula milk powder. The invention provides infant formula milk powder for the first time, the infant formula milk powder comprises 2 '-fucosyllactose and lactose-N-neotetraose, and the mass ratio of the 2'-fucosyllactose to the lactose-N-neotetraose is (1-5.5): 1. The infant formula milk powder can improve intestinal inflammation and / or microbial disorder.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention provides a Kitasatospora xanthophycea JY01 strain and application thereof, the strain is separated from intestinal tracts of spring silkworms, has good disease-resistant and growth-promoting effects, and is specifically expressed in that cellulase, beta-1, 3-glucanase, siderophore and auxin IAA can be secreted; pot experiments show that the biocontrol efficiency of the microbial inoculum to wheat stalk rot is 57.90%, the biocontrol efficiency of the microbial inoculum to corn stalk rot is 46.41%, and the plant height and fresh weight are both significantly increased. The microbial agent is expected to be applied to preparation of biological bacterial fertilizer for effectively preventing and controlling soil-borne fungal diseases.

The invention relates to the technical field of microorganisms, in particular to application of lactobacillus rhamnosus KF7 in improving intestinal barrier injury and regulating intestinal flora and functional food containing the lactobacillus rhamnosus KF7. The invention provides application of lactobacillus rhamnosus KF7 in preparation of a product for improving intestinal barrier injury and / or regulating intestinal flora. The preservation number of the lactobacillus rhamnosus KF7 is CGMCC (China General Microbiological Culture Collection Center) NO.6430. The invention further provides application of the lactobacillus rhamnosus KF7 in preparation of a product for improving intestinal barrier injury and / or regulating intestinal flora. The invention discloses the novel application of the caseus rhamnosus KF7 in the aspects of improving the normal intestinal epithelial barrier function, protecting the normal intestinal epithelial barrier from lipopolysaccharide induced barrier injury, recovering animal intestinal barrier injury caused by rhythm disorder, regulating intestinal flora disorder and improving growth, development and metabolic states for the first time. The method can be used for producing functional food products such as fermented milk, lactic acid bacteria beverages, probiotic powder, viable bacteria water, milk powder and cheese.

The invention discloses a vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions and a preparation method and application thereof, the vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions comprises three layers, namely a core layer, a middle layer and an outer layer from inside to outside in sequence; the core layer is formed by coating vitamin K2 with a zein-lac hydrophobic core, the middle layer is a pea protein-pectin electrostatic compound, and the outer layer is sodium alginate and chitosan double-network gel. The micro-capsule system provided by the invention can be tightly combined in a gastric acid environment after being orally taken, the release of active ingredients in the stomach is reduced, and then the micro-capsule system stays at intestinal mucosa for a long time and slowly releases contents, so that the functions of the micro-capsule system are slowly presented outside, the half-life period is prolonged, and the action effect is improved. Vitamin K2 directly or indirectly participates in and regulates various physiological processes related to health, and plays an important role in the aspects of maintaining bone health, preventing cardiovascular diseases, protecting nerves, improving metabolism and the like.

A surgical anchor device for being anchored on the mucous membrane of the inner wall of the intestine, the device having a temporary anchor element presenting anchoring that can be modified in a controlled manner and having a first substantially cylindrical multiply-perforated wall presenting properties of radial elasticity whereby the first wall presents an outer diameter that can be varied in controlled manner, wherein a portion of the inner surface of the first wall is lined with an independent leakproof inner sheath having only its longitudinal ends fastened to the anchor element to define a suction chamber between the inner sheath and the first wall, the temporary anchor element being coupled to a flexible or semi-rigid tube extending outside the anchor element, an open end of the injection-suction tube opening out into the suction chamber enabling air to be injected into or sucked out from the suction chamber.

The invention relates to the field of ulcerative colitis, and discloses a multi-parameter monitoring system for evaluating the intestinal barrier function of ulcerative colitis, which is used for realizing the goal of automatically adjusting a treatment scheme according to a monitoring result by constructing a closed-loop feedback treatment system. According to the invention, by designing the nanoprobe of which the surface is modified with a specific binding element and combining with a swallowing capsule endoscopy, real-time imaging and molecular level dynamic tracking of the intestinal barrier are realized, genetically engineered bacteria are constructed to quantify intestinal permeability abnormality and local inflammation level, and an intestinal barrier function damage score and a disease progress prediction result are output; individual monitoring is achieved through transfer learning, ultrasonic elastography, optical coherence tomography, wearable equipment for measuring intestinal electric field impedance spectroscopy and other technologies are adopted, an intestinal wall mechanics-electrophysiology composite parameter set is obtained, and the evaluation accuracy is improved.

The invention relates to the technical field of pet health care, in particular to a probiotic composite additive for pet intestinal health and a preparation method of the probiotic composite additive. Comprising the following basic components in percentage by mass: 40% of lactobacillus complex, 10% of bifidobacterium complex, 10% of saccharomyces boulardii, 10% of prebiotic complex, 10% of natural digestive enzyme, 10% of functional plant extract, 10% of carrier and the like. 30% of a bifidobacterium complex group; 15% of saccharomyces boulardii; 8% of a prebiotic compound; 5% of natural digestive enzyme; and 2% of a functional plant extract. The multiple probiotics have a synergistic effect, the effect is better, the prebiotics promote proliferation of the probiotics and can enhance the effect of the additive, meanwhile, through drying treatment, the product is good in stability, long in shelf life and small in package design, the additive can be conveniently added to pet food, intestinal health of pets can be effectively improved, and the preparation method is simple and suitable for large-scale production.

The invention relates to the technical field of functional microorganism screening and application, and particularly provides a strain of lactobacillus plantarum and an application of the lactobacillus plantarum in improvement of intestinal inflammation and repair of intestinal mucosa injury. The plant lactobacillus is preserved in the China General Microbiological Culture Collection Center (CGMCC for short) on August 1, 2024, the address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number of the plant lactobacillus is CGMCC No.31521. The strain has remarkable antioxidant, bacteriostatic and anti-inflammatory effects, can repair intestinal barrier injury of mice with colitis, promote renewal of intestinal stem cells, promote growth of intestinal beneficial bacteria and inhibit proliferation of harmful bacteria, can be widely applied to prevention and treatment of enteritis, and has a wide market prospect.

The invention belongs to the technical field of microorganisms, and relates to high-activity plant lactobacillus KL100 for relieving anxiety and depression and application of the high-activity plant lactobacillus KL100. The plant lactobacillus provided by the invention is KL100, is preserved in the China General Microbiological Culture Collection Center (CGMCC), has a preservation number of CGMCC No.27192, and is classified and named as the plant lactobacillus. The plant lactobacillus is KL100, has a good gastrointestinal passing rate, shows a breeding characteristic in the stomach after being embedded, is improved in cholate-resistant survival rate, and can be used for preparing the plant lactobacillus. According to the application disclosed by the invention, the expression of IL-1beta and TNF-alpha in a mouse body can be effectively reduced, the expression of IL-10 can be improved, and the secretion of 5-hydroxytryptamine by chromaffin cells in intestinal tracts can be promoted, so that anxiety and depression can be relieved, the strain resource is expanded, the development of the biological medicine field is promoted, and a new direction is provided for treating anxiety and depression.

The invention relates to a method for identifying a disease microorganism-metabolite combined marker based on a host-flora co-metabolism model. The method comprises the following steps: processing microbiome data; setting diet constraint conditions; determining classification composition of intestinal microorganisms of each individual, mapping abundance of each microorganism to a human microorganism genome scale metabolism model, and constructing an individualized flora metabolism network model; carrying out metabolic flow simulation on the constructed flora metabolism network model; integrating the constructed flora metabolism network model with the host metabolism network model, and predicting the metabolic flow and metabolite change of the whole system; and establishing a disease classifier based on a random forest machine learning algorithm to identify the microorganism-metabolite combined marker. According to the method, the complex metabolic process between the human body and the intestinal flora is restored in a metabolic network modeling and metabolic flow simulation mode, the method has the non-invasive characteristic, the time and economic cost is remarkably reduced, and meanwhile, the method has a great advantage in accuracy.

The invention relates to a bifidobacterium animalis subsp. Lactis YYSJ001 with a blood sugar reducing effect and application of the bifidobacterium animalis subsp. Lactis YYSJ001. The classification name of the strain is bifidobacterium animalis subsp. Lactis, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.33471. The invention further relates to a preparation method of the bifidobacterium animalis subsp. Lactis YYSJ001. The bacterial strain has good artificial gastric juice resistance, artificial intestinal juice resistance and intestinal tract adhesion ability, has an inhibition effect on numerous pathogenic bacteria such as escherichia coli, staphylococcus aureus, salmonella, klebsiella pneumoniae and quail chicken enterococcus, and can stimulate intestinal cells to generate glucagon-like peptide-1, so that the bacterial strain can be applied to preparation of various pathogenic bacteria. Diseases of diabetic mice can be effectively improved, and the compound can be used for preparing products for preventing and treating diabetes or assisting in reducing blood sugar.

The invention relates to the field of microorganisms, and discloses an aspergillus cristatus strain and application thereof. The preservation number of the aspergillus cristatus provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.41727. The aspergillus cristatus provided by the invention can produce chymosin at high yield, has excellent curding activity and relatively low proteolytic activity, and can reduce the bitter taste of dairy products and improve the yield; the aspergillus cristatus provided by the invention not only can shorten the fermentation time of the dairy product, improve the cream flavor of the dairy product, reduce the peculiar smell of the dairy product, balance the sourness and sweetness of the dairy product and improve the cinnamon flavor, but also has intestinal colonization ability, and has the potential of improving the flavor level of the dairy product and becoming intestinal probiotics.

To provide beta-1,3-glucan, and to provide uses thereof for regulating immunity in the human body, which are methods for treating and / or preventing high cholesterol, diabetes, and allergies, and methods for treating and / or preventing intestinal inflammation.SOLUTION: Provided is a composition for oral administration for alleviating symptoms associated with intestinal inflammation in humans, the composition containing an effective amount of beta-1,3-glucan dried to a moisture content of about 40% or less from Euglena grown by fermentation, the beta-1,3-glucan not containing beta-1,6-glycosidic bonds, the effective amount being between 0.1 mg of beta-1,3-glucan / kg body weight and 100 mg of beta-1,3-glucan / kg body weight.SELECTED DRAWING: Figure 1

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The application belongs to the field of intestinal microbiology, and discloses a new mucinophilic Akkermansia with improved obesity and glycolipid metabolism, wherein the mucinophilic Akkermansia strain is Akk-101 and AMY001. The preservation number of Akk-101 is CGMCC No. 40786, and the preservation number of AMY001 is CGMCC No. 46141. The Akk-101 and AMY001 strains in the application are different from standard strains in nucleotide consistency and physiological and biochemical indexes, have better acid-base tolerance and colonization capacity than the standard strains, can more effectively inhibit the accumulation of liver cell lipids, reduce the fat deposition in nematodes, and have the effects of weight loss and improvement of glycolipid metabolism, so that related products can be effectively developed based on the strains.

The invention discloses bifidobacterium breve and application thereof in relieving Alzheimer's disease, and belongs to the technical field of probiotics. The preparation method comprises the following steps: separating 18 bifidobacterium strains from feces of children aged 0-3 years old, analyzing and identifying the 18 bifidobacterium strains including bifidobacterium longum, bifidobacterium breve and bifidobacterium animalis, and screening out the bifidobacterium breve LE4 with potential Alzheimer's disease relieving capacity through in-vitro oxidation resistance and LPS (Lipopolysaccharide) removal capacity. The method comprises the steps of behavioral experiments (nesting experiments, open field experiments and water maze experiments), histopathologic analysis, molecular biological detection and the like. The multi-target AD intervention effects of improving the cognitive function, reducing A beta deposition and tau protein phosphorylation, relieving neuroinflammation, enhancing synaptic plasticity, repairing intestinal barriers, adjusting intestinal flora and metabolites and the like of the LE4 strain are comprehensively evaluated, and a new strategy is provided for promoting AD micro-ecological treatment.

The invention discloses lactobacillus plantarum capable of relieving enteritis and toxicity of polystyrene nano-plastics, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) NO.31420. The lactobacillus plantarum can be used for relieving enteritis and toxicity of polystyrene nano-plastics. The strain is obtained by separating and purifying baby feces, and can grow on an MRS culture medium, and the bacterial colony is round, off-white, smooth and opaque. Experiments show that the lactobacillus plantarum can effectively adsorb PS-NPs, promote the PS-NPs to be discharged along with excrement, reduce accumulation of the PS-NPs in organs, and significantly reduce toxicity and inflammatory response of organs such as liver and kidney of mice. In addition, the strain can repair the intestinal barrier function, regulate liver metabolism and relieve enteritis symptoms. The invention further provides a probiotic preparation containing the strain, and the probiotic preparation can be prepared into granules, capsules, tablets or oral liquid and the like and is used for preventing or treating intestinal injury and inflammatory diseases caused by PS-NPs. The strain is safe and efficient, and has a wide application prospect.

The invention relates to the technical field of microorganisms, in particular to a culture medium and a method for culturing Ackermania muciniphila for activating Amuc-1260 by using lambda-carrageenan as a carbon source, according to the culture method, the lambda-carrageenan is used for replacing a traditional carbon source, thallus growth and proliferation can be remarkably promoted, the effect is optimal under the condition of 2.00 g / L, and the culture cost is low. Compared with the conventional carbon source (glucose), the carbon source is improved by 92.91%. Further research finds that the lambda-carrageenan can induce the Akk bacteria to up-regulate the expression of glycoside hydrolase such as Amuc-1260 and enhance the activity of pathways such as glycosaminoglycan degradation, amino acid metabolism and insulin signals, so that the metabolic adaptability and energy utilization efficiency of the bacteria are improved. Meanwhile, the Akk bacteria secrete more functional short-chain fatty acids such as acetic acid, propionic acid and the like under the condition, and have the effects of regulating intestinal health and maintaining metabolic homeostasis. The invention provides a new theoretical basis and technical support for large-scale culture of Akk bacteria and development of a metabiotic product.

The invention discloses a multi-modal animal abnormal data behavior classification method and device which are applied to the technical field of data processing, and the method comprises the steps: obtaining abnormal data of a target animal in different development stages; the abnormal data comprises behavior video data and intestinal flora data of the same animal; performing feature extraction on the behavior video data to obtain behavior features representing animal action modes; analyzing the intestinal flora data to obtain intestinal flora characteristics; performing multi-modal data fusion on the behavior characteristics and the intestinal flora characteristics to generate fusion characteristics; inputting the fusion features into a pre-trained data model, classifying animal behaviors through the data model, and outputting a classification result; through the behavior-flora multi-modal fusion strategy, the classification accuracy is improved, and clues are provided for early intervention.

The invention discloses a method and system for predicting juvenile depression based on intestinal flora, and relates to the technical field of bioinformatics and artificial intelligence, and the method comprises the steps: firstly, obtaining an original sequence of a microbiome, carrying out the preprocessing of the original sequence of the microbiome, and obtaining a feature matrix; and screening core flora characteristics with stable trans-folding by adopting characteristic importance evaluation and interpretability analysis based on a gradient boosting decision tree. A mixed weighted graph is constructed based on Spearman correlation and a proximity relationship, and an absolute value of a correlation coefficient is taken as an edge weight and an edge density is adjusted through a threshold adaptive strategy. And finally, through an improved graph attention neural network, based on edge weight attention, layer normalization and random inactivation, enhancing robustness, and adopting adaptive optimization to complete parameter learning. And determining a dynamic classification threshold according to the AUC of the target patient, and outputting a sample discrimination result and confidence. According to the method, the accuracy, stability and biological interpretability of juvenile depression recognition are remarkably improved.

The invention relates to the technical field of feed products, in particular to a fatty acid composition and application thereof in preparation of products for improving intestinal health. The fatty acid composition comprises arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, butyric acid and lauric acid, or a precursor substance capable of releasing the fatty acid in the digestive tract, and the mass of the fatty acid composition is calculated according to the mass of the arachidonic acid, the mass of the docosahexaenoic acid, the mass of the eicosapentaenoic acid, the mass of the butyric acid and the mass of the lauric acid. The additive is prepared from the following components in parts by weight: 7-10 parts of arachidonic acid, 3-7 parts of docosahexaenoic acid, 3-7 parts of eicosapentaenoic acid, 2-5 parts of butyric acid and 1-3 parts of lauric acid. The composition can effectively relieve inflammation and diarrhea, regulate intestinal flora and improve intestinal health, and drug resistance is not prone to being generated.

The invention discloses an Ansys-based intestinal tract wall and wall surface motion modeling method and device. The method comprises the following steps: S1, establishing a human body real intestinal tract three-dimensional geometric model; s2, preprocessing the three-dimensional geometric model of the intestinal tract; s3, intestinal wall material parameters are set, and an intestinal wall is simulated; s4, separating a wall surface solid domain from the modified intestinal tract three-dimensional geometric model, carrying out wall surface simulation setting, and dividing grids; s5, by setting load and boundary conditions, wall surface movement setting is achieved in the form of simulating intestinal tract movement; wherein the motion forms comprise creeping, sectional contraction and swinging contraction; and S6, setting solver parameters, and simulating intestinal tract wall and wall surface movement. Loads and constraint conditions can be flexibly adjusted, the variability and adaptability of the model are remarkably enhanced, and the cost of sacrificing the real reflection capability of the model to the actual physiological state is not taken.

The invention discloses an intestinal strain capable of effectively regulating uric acid metabolism, a microbial agent of the intestinal strain and application of the intestinal strain in uric acid reducing products, and belongs to the technical field of microorganisms. According to the enterococcus pluvialis ZQ205, the enterococcus pluvialis ZQ205 which is free of toxic and side effects and capable of effectively relieving and treating the hyperuricemia is found for the first time, and the collection number of the enterococcus pluvialis ZQ205 in the China Center for Type Culture Collection is CCTCC NO: M 2025844; the strain can significantly reduce the levels of uric acid, creatinine and urea nitrogen in serum of mice, can effectively reduce the levels of inflammatory factors such as IL-6 and TNF-alpha in serum of hyperuricemia mice, and can improve kidney injury caused by hyperuricemia.

The invention provides a capsule endoscope intestinal panoramic image splicing method and device, a computer readable storage medium and computer equipment. The method comprises the following steps: performing feature matching on an original intestinal tract image set acquired by a capsule endoscope to obtain a feature point set of each image of the original intestinal tract image set; performing polar coordinate expansion on each original intestinal image to obtain a rectangular intestinal image and a new feature point set corresponding to the feature point set in the rectangular intestinal image; calculating the displacement difference of each new feature point according to the coordinates of each new feature point of the new feature point sets of the two adjacent frames of rectangular intestinal tract images; cutting according to the displacement difference to obtain a stepping region image between two adjacent frames of original intestinal tract images; performing polar coordinate expansion on the stepping area image to obtain a newly added image segment; and splicing the newly added image segments in sequence to obtain an intestinal panoramic image. According to the method, a more accurate real stepping distance is obtained through calculation, and the smoothness and continuity of the image splicing position can be improved.